Antibacterial and Synergy of Berberines with Antibacterial Agents against Clinical Multi-Drug Resistant Isolates of Methicillin-Resistant Staphylococcus aureus MRSAReportar como inadecuado




Antibacterial and Synergy of Berberines with Antibacterial Agents against Clinical Multi-Drug Resistant Isolates of Methicillin-Resistant Staphylococcus aureus MRSA - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Research Center for Natural Medicines, Kunming General Hospital, PLA, Kunming 650032, China

2

Kunming Medical College, Kunming 650032, China

3

School of Basic Medical Sciences, Yunnan Traditional Chinese Medical College, Kunming 650500, China

4

Center for Infectious Diseases, Kunming General Hospital, PLA, Kunming 650032, China





*

Author to whom correspondence should be addressed.



Abstract Antibacterial activity of berberine Ber and 8-acetonyl-dihydroberberine A-Ber alone and combined uses with antibacterial agents ampicillin AMP, azithromycin AZM, cefazolin CFZ and levofloxacin LEV was studied on 10 clinical isolates of SCCmec III type methicillin-resistant Staphylococcus aureus MRSA. Susceptibility to each agent alone was tested using a broth microdilution method and the chequerboard and time-kill tests for the combined evaluations, respectively. The alone MICs-MBCs mg-mL ranges were 32–128-64–256 Ber and 32-128-128-512 A-Ber. Significant synergies were observed for the Ber A-Ber-AZM and Ber A-Ber-LEV combinations against 90% of the tested MRSA strains, with fractional inhibitory concentration indices FICIs values ranged from 0.188 to 0.500. An additivity result was also observed for the Ber-AZM combination by time-kill curves. These results demonstrated for the first time that Ber and A-Ber enhanced the in vitro inhibitory efficacy of AZM and LEV to a same extent, which had potential for further investigation in combinatory therapeutic applications of patients infected with MRSA.

Keywords: anti-MRSA; synergy; 8-acetonyl-dihydroberberine; levofloxacin; FICI anti-MRSA; synergy; 8-acetonyl-dihydroberberine; levofloxacin; FICI





Autor: Guo-Ying Zuo 1, Yang Li 1,2, Jun Han 3, Gen-Chun Wang 1, Yun-Ling Zhang 1 and Zhong-Qi Bian 4,*

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados